Evidence map›Paper›PMID 37313020›Full record

ReviewBasic and clinical neuroscience

Chondroitinase ABC Administration in Locomotion Recovery After Spinal Cord Injury: A Systematic Review and Meta-analysis.

Mahmoud Yousefifard, Atousa Janzadeh, Kosar Mohamed Ali, Mohammad Hossein Vazirizadeh-Mahabadi, Arash Sarveazad, Arian Madani Neishaboori, Mostafa Hosseini

Abstract readReview
In one paragraph

Review in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mahmoud YousefifardDepartment of Physiology, Researcher at Physiology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-5181-4985
Atousa JanzadehRadiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-9901-364X
Kosar Mohamed AliDepartment of Respiratory Medicine, School of Medicine, University of Sulaimani, Sulaimani, Iraq.ORCID https://orcid.org/0000-0001-5533-2924
Mohammad Hossein Vazirizadeh-MahabadiResearcher at Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2435-9985
Arash SarveazadColorectal Research Center, Researcher at Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-9273-1940
Arian Madani NeishabooriResearcher at Physiology Research Centre, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-1920-9299
Mostafa HosseiniDepartment of Epidemiology and Biostatistics School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-1334-246X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The present systematic review and meta-analysis aims to conduct a comprehensive and complete search of electronic resources to investigate the role of administrating Chondroitinase ABC (ChABC) in improving complications following Spinal Cord Injuries (SCI). Methods: MEDLINE, Embase, Scopus, and Web of Sciences databases were searched until the end of 2019. Two independent reviewers assessed the studies conducted on rats and mice and summarized the data. Using the STATA 14.0 software, the findings were reported as pooled standardized mean differences (SMD) with 95% confidence intervals (CI). Results: A total of 34 preclinical studies were included. ChABC administration improves locomotion recovery after SCI (SMD=0.90; 95% CI: 0.61 to 1.20; P<0.001). The subgroup analysis showed that the differences in the SCI model (P=0.732), the severity of the injury (P=0.821), the number of ChABC administrations (P=0.092), the blinding status (P=0.294), the use of different locomotor score (P=0.567), and the follow-up duration (P=0.750) have no effect on the efficacy of ChABC treatment. Conclusion: The findings of the present study showed that prescribing ChABC has a moderate effect in improving locomotion after SCI in mice and rats. However, this moderate effect introduces ChABC as adjuvant therapy and not as primary therapy.

Indexed as

AnimalChondroitinase ABCLocomotionSpinal cord injuries

Identifiers

PMID37313020
PMCPMC10258590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.